NCT03890770

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of BMS-986165 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Renal Impairment and in Participants With End-Stage Renal Disease (ESRD) on Hemodialysis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate BMS-986165 in participants with different levels of kidney function.

Conditions

• Renal Impairment
• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	BMS-986165	Oral administration

Timeline

• Start date: 2019-04-04
• Primary completion: 2020-02-07
• Completion: 2020-02-13
• First posted: 2019-03-26
• Last updated: 2021-03-12

Locations

6 sites across 4 countries: United States, Czechia, Hungary, Poland

Regulatory

• FDA-regulated drug study